---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-024095"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:28:27.854393+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocugen Q1 2025 net loss $0.05/sh; cash $38.1M; OCU400 Phase 3 on track for mid-2026 BLA/MAA

## Summary
- Cash & restricted cash $38.1M as of Mar 31, 2025, down from $58.8M at Dec 31, 2024; runway into Q1 2026.
- Operating expenses $16.0M (R&D $9.5M, G&A $6.5M) vs $13.2M in Q1 2024; net loss per share unchanged at $0.05.
- OCU400 Phase 3 liMeliGhT RP trial recruiting; BLA/MAA filings targeted by mid-2026; ATMP classification from EMA.
- OCU410ST Phase 2/3 pivotal trial for Stargardt disease to start mid-2025; BLA filing target 2027.
- OCU410 for GA: Phase 2 dosing complete; 12-month data shows 4-line VA gain and 41% slower lesion growth.

## SEC filing metadata
- accession: 0001628280-25-024095
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828025024095/0001628280-25-024095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828025024095/ocgn-20250509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-024095
- JSON: https://secwatch.observer/filing/0001628280-25-024095.json
- Plain text: https://secwatch.observer/filing/0001628280-25-024095.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.